The Catholic University of Korea Industry-academic Cooperation Foundation

The Catholic University of Korea Industry-academic Corporation Foundation

Chul-Woo Yang

Mi-La Cho

Min-Jung Park

Seon-Yeong Lee

Dong-Yun Shin

Sung-Hee Lee

Eun-Kyung Kim

Hye-Jin Son

Jong-Young Choi

Jae-Kyung Kim

Sung-Hwan Park

Joo-Yeon Jhun

Eun-Ji Yang

Hee-yeon Kim

Hyeon-Beom Seo

Seung-Hun Lee

Jae-yoon Ryu

Kyoung-Woon Kim

Seong-Hyeok Park

Jae-Kyeong Byun

Ye-Been Yim

Byung-Ha Chung

Keun-Hyung Cho

Se-Young Kim

The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-&#x3b1;, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

Compound having immune disease treatment effect and use thereof

The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.

Kit for monitoring immune status after transplant and method for monitoring immune status using same

Growing community of inventors

Seoul, South Korea

Chul-Woo Yang